Percutaneous Cryoablation of Primary Liver Tumours: Systematic Review
International Journal of Current Pharmaceutical Review and Research · 28.02.2026 · 18 (02)
DOI: 10.25258/ijcpr.18.2.294 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 28.02.2026. Verfasst von Pankaj Goyal und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Aim
Percutaneous cryoablation has emerged as an important image-guided locoregional therapy for selected patients with primary liver tumors, especially hepatocellular carcinoma (HCC), who are not ideal candidates for surgery or transplantation. The present paper aims to review the scientific basis, procedural technique, patient selection, outcomes, complications, and contemporary role of percutaneous cryoablation in the management of primary liver tumors, with emphasis on HCC and limited reference to intrahepatic cholangiocarcinoma where appropriate. Materials and Methods: This paper is a structured narrative review based on peer-reviewed clinical studies, expert consensus documents, and guideline-oriented sources addressing percutaneous cryoablation for primary liver tumors. Core evidence was drawn from a large single-center experience of 299 hepatic tumors treated in 186 patients, a focused review of cryoablation for HCC, a prospective multicenter comparison of cryoablation versus radiofrequency ablation (RFA) in elderly patients with small HCC, and recent expert guidance on local ablation for HCC. A key technical advantage is direct visualization of the developing ice ball on CT and MRI, permitting intraprocedural assessment of coverage and protection of adjacent critical structures such as the gallbladder, major bile ducts, bowel, diaphragm, and large vessels.
Results
Across published series, percutaneous cryoablation is technically feasible, reasonably effective, and most successful in tumors below 4 cm. In the large single-center study, technical success was 94.6% and 3-month technique efficacy was 89.5%, with clearly superior outcomes in tumors under 4 cm compared with those 4 cm or larger. Local tumor progression adjusted for repeat treatment was 23.3% overall, but only 18.0% for tumors under 4 cm compared with 63.3% for larger lesions. In a prospective multicenter study of elderly patients with small HCC, cryoablation and RFA showed similar 1-, 3-, and 5-year overall survival and similar major complication rates, while cryoablation demonstrated lower local tumor progression for lesions larger than 3 cm.
Conclusion
Percutaneous cryoablation is a valuable minimally invasive treatment option for selected primary liver tumors, especially early HCC in patients unsuitable for resection or transplantation and in cases where tumor location makes heat-based ablation less desirable. Its principal strengths are accurate ice-ball visualization, relative preservation of adjacent large vessels, less intraprocedural pain, and potentially better local control for somewhat larger small tumors. Its limitations include reduced efficacy in tumors 4 cm or larger, the need for careful post-procedure monitoring, and the persistence of uncommon but serious systemic complications. Overall, current evidence supports cryoablation as an important component of the ablative armamentarium for primary liver tumors when individualized multidisciplinary selection is applied.
Zitieren
APA
Goyal, P., Khan, A., & Ahirwar, L. (2026). Percutaneous Cryoablation of Primary Liver Tumours: Systematic Review. International Journal of Current Pharmaceutical Review and Research, 18(02). https://doi.org/10.25258/ijcpr.18.2.294
Vancouver
Goyal P, Khan A, Ahirwar L. Percutaneous Cryoablation of Primary Liver Tumours: Systematic Review. International Journal of Current Pharmaceutical Review and Research. 2026;18(02). doi:10.25258/ijcpr.18.2.294
BibTeX
@article{Goyal2026,
author = {Goyal, Pankaj and Khan, Adnan and Ahirwar, Laxman},
title = {Percutaneous Cryoablation of Primary Liver Tumours: Systematic Review},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {02},
doi = {10.25258/ijcpr.18.2.294}
}
EUVIMED